Government-Owned Inventions; Availability for Licensing, 6891-6892 [2021-01490]

Download as PDF Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices false accuracy claims and engage in unfair, discriminatory conduct.6 DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2021–01430 Filed 1–22–21; 8:45 am] National Institutes of Health BILLING CODE 6750–01–P Government-Owned Inventions; Availability for Licensing DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY: National Institutes of Health, HHS. National Institutes of Health ACTION: National Institute of Dental & Craniofacial Research; Notice of Closed Meeting The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Carol A. Salata at 240–627–3727; csalata@niaid.nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows: SUMMARY: Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: NIDCR Special Grants Review Committee. Date: February 18–19, 2021. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Dental and Craniofacial Research, National Institutes of Health, 6701 Democracy Boulevard, Room 666, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Latarsha J. Carithers, Scientific Review Officer, Scientific Review Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, 6701 Democracy Boulevard, Room 666, Bethesda, MD 20892, 301–594–4859, latarsha.carithers@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) Dated: January 19, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–01486 Filed 1–22–21; 8:45 am] jbell on DSKJLSW7X2PROD with NOTICES BILLING CODE 4140–01–P 6 Prepared Remarks of Commissioner Rohit Chopra at Asia Pacific Privacy Authorities 54th APPA Forum (Dec. 7, 2020), https://www.ftc.gov/ public-statements/2020/12/prepared-remarkscommissioner-rohit-chopra-asia-pacific-privacy. VerDate Sep<11>2014 18:31 Jan 22, 2021 Jkt 253001 Notice. Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens for Human Metapneumovirus Description of Technology: Human metapneumovirus (hMPV) infections have been shown as a common cause of upper and lower respiratory diseases such as bronchiolitis and pneumonia in young children, the elderly, and other immunocompromised individuals. Studies show that infections by the nonsegmented negative strand RNA virus begin with attachment and entry of viral glycoproteins that mediate fusion with host cellular membranes. Like for the human respiratory syncytial virus (hRSV), a viral entry is initiated by the fusion (F) protein. Given its role in hMPV entry, the F protein has thus been a target for eliciting neutralizing antibodies and development of novel protein-based therapeutic vaccines. Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) developed improved recombinant human metapneumovirus (hMPV) F PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 6891 proteins stabilized in the prefusion conformation that can elicit potent neutralizing antibodies against infection. Double and triple stabilized candidates were designed with interand intraprotomer disulfide mutations that increase protein production and show improved antigenic recognition by prefusion-specific antibodies. These second-generation immunogens constitute an improvement over the first generation constructs and are characterized by additional stabilization that results in optimal neutralization responses. The second-generation stabilized prefusion hMPV F immunogens may be an ideal vaccine immunogen to elicit broad potent neutralizing antibodies against metapneumovirus infection, particularly in children and immunocompromised adults. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Potential Commercial Applications: • A promising vaccine immunogen to elicit broad potent neutralizing antibodies against metapneumovirus infection, particularly in children and immunocompromised adults. Competitive Advantages: • There are no approved vaccines or therapeutics against the second leading cause of pediatric viral lower respiratory tract infection in infants and young children. • Second-generation hMPV F immunogens induce higher titer neutralizing responses than firstgeneration versions in mice. Development Stage: Preclinical Research. Inventors: Peter D. Kwong (NIAID); Guillaume Stewart-Jones (NIAID); John R. Mascola (NIAID); Ursula J. Buchholz (NIAID); Peter L. Collins (NIAID); Jason Gorman (NIAID); Li Ou,(NIAID); Tongquing Zhou (NIAID); Baoshan Zhang (NIAID); Wing-Pui Kong (NIAID); Yaroslav Tsybovsky (NCI). Publications: Liu, P., et al (2013). A live attenuated human metapneumovirus vaccine strain provides complete protection against homologous viral infection and crossprotection against heterologous viral infection in BALB/c mice. Clinical and Vaccine Immunology, 20(8), 1246–1254. Battles, M.B., et al, (2017). Structure and immunogenicity of pre-fusionstabilized human metapneumovirus F glycoprotein. Nature communications, 8(1), 1–11. Intellectual Property: HHS Reference Number E–131–2019 includes U.S. Provisional Patent Application Number 63/017,581, filed on 04/29/2020. E:\FR\FM\25JAN1.SGM 25JAN1 6892 Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices Licensing Contact: To license this technology, please contact Carol A. Salata at 240–627–3727; csalata@ niaid.nih.gov. The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following: Dated: January 14, 2021. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. Dated: January 8, 2021. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. Fields of Use Applying to Intellectual Property Group B [FR Doc. 2021–01487 Filed 1–22–21; 8:45 am] [FR Doc. 2021–01490 Filed 1–22–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Ziopharm Oncology, Inc. (‘‘Ziopharm’’), headquartered in Boston, MA. DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before February 9, 2021 will be considered. SUMMARY: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240) 276–5484; Email: andy.burke@nih.gov. SUPPLEMENTARY INFORMATION: ADDRESSES: Intellectual Property jbell on DSKJLSW7X2PROD with NOTICES Group B E–173–2020: T Cell Receptors Recognizing R273C or Y220C Mutation in P53 1. U.S. Provisional Patent Application 63/074,747, filed September 4, 2020 (E–173–2020–0–US–01). The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. VerDate Sep<11>2014 18:31 Jan 22, 2021 Jkt 253001 ‘‘Development, manufacture and commercialization of autologous, peripheral blood T cell therapy products engineered by transposon-mediated gene transfer to express T cell receptors reactive to mutated P53, as claimed in the Licensed Patent Rights, for the treatment of human cancers. Specifically excluded from this field of use are CRISPR-engineered peripheral blood T cell therapy products for the treatment of human cancers. Development, manufacture and commercialization of companion diagnostics approved or cleared by the FDA or equivalent foreign regulatory agency for Licensee-proprietary T cell therapy products.’’ Intellectual Property Group B is primarily directed to isolated TCRs reactive to mutated tumor protein 53 (TP53 or P53), within the context of several HLAs. P53 is the archetypal tumor suppressor gene and the most frequently mutated gene in cancer. Contemporary estimates suggest that >50% of all tumors carry mutations in P53. Because of its prevalence in cancer and its restricted expression to precancerous and cancerous cells, this antigen may be targeted on mutant P53expressing tumors with minimal normal tissue toxicity. This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment of Humans With Short Stature AGENCY: National Institutes of Health, HHS. ACTION: Notice. The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to EpifiZa Inc. of Montreal, QC (Canada). DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before February 9, 2021 will be considered. SUMMARY: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Richard T. Girards, Jr., Esq., MBA, Senior Technology Transfer Manager, National Institutes of Health, NCI Technology Transfer Center by email (richard.girards@nih.gov) or phone (240–276–6825). SUPPLEMENTARY INFORMATION: ADDRESSES: Intellectual Property E–003–2014: Agents That Specifically Bind Matrilin–3 and Their Use/Cartilage Targeting Agents and Their Use 1. United States Provisional Patent Application No. 61/927,904, filed 15 January 2014 (HHS Reference No. E– 003–2014–0–US–01); 2. United States Patent No. 10,323,083, issued 18 June 2019 (HHS Reference No. E–003–2014–0–US–06); 3. United States Patent Application No. 16/391,101, filed 22 April 2019 E:\FR\FM\25JAN1.SGM 25JAN1

Agencies

[Federal Register Volume 86, Number 14 (Monday, January 25, 2021)]
[Notices]
[Pages 6891-6892]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01490]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Carol A. Salata at 240-627-3727; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows:

Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens for 
Human Metapneumovirus

    Description of Technology:
    Human metapneumovirus (hMPV) infections have been shown as a common 
cause of upper and lower respiratory diseases such as bronchiolitis and 
pneumonia in young children, the elderly, and other immunocompromised 
individuals. Studies show that infections by the non-segmented negative 
strand RNA virus begin with attachment and entry of viral glycoproteins 
that mediate fusion with host cellular membranes. Like for the human 
respiratory syncytial virus (hRSV), a viral entry is initiated by the 
fusion (F) protein. Given its role in hMPV entry, the F protein has 
thus been a target for eliciting neutralizing antibodies and 
development of novel protein-based therapeutic vaccines.
    Researchers at the Vaccine Research Center (VRC) of the National 
Institute of Allergy and Infectious Diseases (NIAID) developed improved 
recombinant human metapneumovirus (hMPV) F proteins stabilized in the 
prefusion conformation that can elicit potent neutralizing antibodies 
against infection. Double and triple stabilized candidates were 
designed with inter-and intraprotomer disulfide mutations that increase 
protein production and show improved antigenic recognition by 
prefusion-specific antibodies. These second-generation immunogens 
constitute an improvement over the first generation constructs and are 
characterized by additional stabilization that results in optimal 
neutralization responses.
    The second-generation stabilized prefusion hMPV F immunogens may be 
an ideal vaccine immunogen to elicit broad potent neutralizing 
antibodies against metapneumovirus infection, particularly in children 
and immunocompromised adults.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
    Potential Commercial Applications:
     A promising vaccine immunogen to elicit broad potent 
neutralizing antibodies against metapneumovirus infection, particularly 
in children and immunocompromised adults.
    Competitive Advantages:
     There are no approved vaccines or therapeutics against the 
second leading cause of pediatric viral lower respiratory tract 
infection in infants and young children.
     Second-generation hMPV F immunogens induce higher titer 
neutralizing responses than first-generation versions in mice.
    Development Stage: Preclinical Research.
    Inventors: Peter D. Kwong (NIAID); Guillaume Stewart-Jones (NIAID); 
John R. Mascola (NIAID); Ursula J. Buchholz (NIAID); Peter L. Collins 
(NIAID); Jason Gorman (NIAID); Li Ou,(NIAID); Tongquing Zhou (NIAID); 
Baoshan Zhang (NIAID); Wing-Pui Kong (NIAID); Yaroslav Tsybovsky (NCI).
    Publications: Liu, P., et al (2013). A live attenuated human 
metapneumovirus vaccine strain provides complete protection against 
homologous viral infection and cross-protection against heterologous 
viral infection in BALB/c mice. Clinical and Vaccine Immunology, 20(8), 
1246-1254.
    Battles, M.B., et al, (2017). Structure and immunogenicity of pre-
fusion-stabilized human metapneumovirus F glycoprotein. Nature 
communications, 8(1), 1-11.
    Intellectual Property: HHS Reference Number E-131-2019 includes 
U.S. Provisional Patent Application Number 63/017,581, filed on 04/29/
2020.

[[Page 6892]]

    Licensing Contact: To license this technology, please contact Carol 
A. Salata at 240-627-3727; [email protected].

    Dated: January 8, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-01490 Filed 1-22-21; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.